News Sentiment

CTSO sentiment intelligence

Cytosorbents Crp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 0.38 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

-2.2% over one week, -4.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

OTC Markets Life Sciences Investor Forum: Dr. Phillip Chan, CEO, and Pete Mariani, CFO, of CytoSorbents with Zacks SCR’s Tom Kerr, CFA

Market Reaction

Balanced read

57/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction -2.2% Price reacting lower
Trend fit Trend inactive -4.6% over four weeks
Fair value -64.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 38
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 8
TradingKey 6
Zacks Small Cap Research 2
TradingView 2
Finviz 2
Quiver Quantitative 2
DonanımHaber 2

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 21
Regulatory and legal 2
Guidance 2
Analyst action 2
Balance sheet 1
Capital return 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-53 of 53
Ad Hoc News Direct company coverage

CytoSorbents Corp stock (US23283M1018): analyst sentiment and low share price keep focus on Nasdaq-l

CytoSorbents Corp (CTSO) shares on Nasdaq are trading at a low nominal level of USD 0.49, despite several Wall Street analysts maintaining significantly higher 12-month price targets, with a consensus of USD 5.38. The company, focused on blood purification therapies, continues to

Tone
Positive 64/100
Event
Analyst action
Published
01 Jun 2026 00:51
Source
Ad Hoc News
Finviz Direct company coverage

CTSO - Cytosorbents Corp Stock Price and Quote

This article provides a comprehensive overview of Cytosorbents Corp (CTSO) stock, including its current price, financial metrics, and recent news. It details key financial data such as market cap, income, sales, and various ratios, alongside performance indicators and analyst rat

Tone
Negative 29/100
Event
Analyst action
Published
29 May 2026 22:12
Source
Finviz
Ad Hoc News Direct company coverage

CytoSorbents Corp stock (US23283M1018): Nasdaq price action and valuation metrics in focus

CytoSorbents Corp (CTSO) shares on the Nasdaq Capital Market continue to trade at low single-digit levels, attracting risk-tolerant investors interested in medical technology stocks. The company, which focuses on blood purification technologies, is currently assessed using revenu

Tone
Neutral 50/100
Event
Market update
Published
29 May 2026 01:39
Source
Ad Hoc News
The Globe and Mail Direct company coverage

Cytosorbents Earnings Call Balances Progress and Pressure

Cytosorbents' Q1 2026 earnings call revealed a combination of cautious optimism and ongoing challenges. The company reported modest revenue growth, driven by international sales outside Germany, alongside strong margins. However, it also faced headwinds from FX losses, regulatory

Tone
Neutral 50/100
Event
Earnings
Published
20 May 2026 23:10
Source
The Globe and Mail